What is the price target for HIMS stock?
22 analysts have analysed HIMS and the average price target is 25.48 USD. This implies a price increase of 31.15% is expected in the next year compared to the current price of 19.43.
NYSE:HIMS • US4330001060
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HIMS & HERS HEALTH INC (HIMS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | TD Cowen | Maintains | Hold -> Hold |
| 2026-03-16 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2026-03-11 | Barclays | Maintains | Overweight -> Overweight |
| 2026-03-10 | Deutsche Bank | Maintains | Hold -> Hold |
| 2026-03-10 | B of A Securities | Upgrade | Underperform -> Neutral |
| 2026-03-10 | Citigroup | Upgrade | Sell -> Neutral |
| 2026-03-09 | Needham | Upgrade | Hold -> Buy |
| 2026-02-25 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-25 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-24 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2026-02-24 | TD Cowen | Maintains | Hold -> Hold |
| 2026-02-24 | BTIG | Downgrade | Buy -> Neutral |
| 2026-02-24 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-02-24 | Truist Securities | Reiterate | Hold -> Hold |
| 2026-02-24 | Citigroup | Maintains | Sell -> Sell |
| 2026-02-09 | TD Cowen | Maintains | Hold -> Hold |
| 2026-02-09 | B of A Securities | Maintains | Underperform -> Underperform |
| 2026-02-09 | Citigroup | Maintains | Sell -> Sell |
| 2026-02-02 | BTIG | Maintains | Buy -> Buy |
| 2026-01-12 | Evercore ISI Group | Initiate | In-Line |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-04 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-04 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-10-21 | Keybanc | Initiate | Sector Weight |
| 2025-09-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 872M 65.49% | 1.477B 69.33% | 2.348B 59.00% | 2.817B 19.99% | 3.358B 19.20% | 3.903B 16.23% | 4.107B 5.23% | 4.722B 14.97% | 5.818B 23.21% | 6.809B 17.03% | 5.048B -25.86% | |
| EBITDA YoY % growth | -16.493M 72.00% | 85.092M 615.93% | 176.19M 107.06% | 335.48M 90.41% | 428.37M 27.69% | 525.79M 22.74% | 650.32M 23.68% | 803.76M 23.59% | 865.06M 7.63% | 1.036B 19.76% | 1.163B 12.26% | |
| EBIT YoY % growth | -26.008M 60.82% | 68.004M 361.47% | 121.688M 78.94% | 160.61M 31.99% | 203.41M 26.65% | 283.45M 39.35% | 420.23M 48.26% | 629.34M 49.76% | 716.18M 13.80% | 834.27M 16.49% | 913.76M 9.53% | |
| Operating Margin | -2.98% | 4.61% | 5.18% | 5.70% | 6.06% | 7.26% | 10.23% | 13.33% | 12.31% | 12.25% | 18.10% | |
| EPS YoY % growth | -0.11 65.63% | 0.54 590.91% | 0.51 -5.56% | 0.58 14.00% | 0.64 9.94% | 1.21 89.66% | 1.90 56.49% | 3.97 109.14% | 5.10 28.53% | 6.55 28.40% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.03 -83.77% | 0.11 -37.82% | 0.17 179.74% | 0.20 149.21% | 0.09 182.84% | 0.14 35.08% | 0.24 45.85% | 0.31 55.19% | 0.19 111.11% | 0.23 64.29% | 0.40 62.50% | 0.41 31.87% |
| Revenue Q2Q % growth | 628.79M 7.30% | 660.44M 21.22% | 736.19M 22.91% | 785.49M 27.14% | 773.04M 22.94% | 799.44M 21.05% | 849.36M 15.37% | 879.67M 11.99% | 932.38M 20.61% | 973.69M 21.80% | 1.003B 18.09% | 1.031B 17.20% |
| EBITDA Q2Q % growth | 50.198M -24.17% | 74.009M 43.16% | 99.506M 82.29% | 109.1M 62.50% | 73.993M 47.40% | 96.639M 30.58% | 112.41M 12.97% | 117.17M 7.40% | 85.782M 15.93% | 93.942M -2.79% | 126.07M 12.15% | 129.03M 10.12% |
| EBIT Q2Q % growth | 11.499M -80.15% | 32.021M -2.83% | 55.752M 206.73% | 61.705M 388.29% | 34.425M 199.37% | 53.448M 66.92% | 72.93M 30.81% | 77.928M 26.29% | 31.62M -8.15% | 39.678M -25.76% | 71.808M -1.54% | 74.868M -3.93% |
All data in USD
22 analysts have analysed HIMS and the average price target is 25.48 USD. This implies a price increase of 31.15% is expected in the next year compared to the current price of 19.43.
HIMS & HERS HEALTH INC (HIMS) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of HIMS & HERS HEALTH INC (HIMS) is 0.03 USD and the consensus revenue estimate is 628.79M USD.
The expected long term growth rate for HIMS & HERS HEALTH INC (HIMS) is 17.66%.